Making the Case for Accelerated Withdrawal of Aducanumab

Manuscript Number: 

22-0262R1

Author(s): 
G. Caleb Alexander, Jerry Avorn, Shannon Brownlee, Cameron Camp, Howard Chertkow, Adriane Fugh-Berman, Sam Gandy, Daniel R. George, Robert Howard, Aaron Kesselheim, Kenneth M. Langa, Eric B. Larson, George Perry, Edo Richard, Vikas Saini, Lon Schneider, Peter Whitehouse

Disclosures

G. Caleb Alexander

  • Consulting Fees:
    Dr. Alexander is past Chair and a current member of FDA’s Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.
    Equity:
    Dr. Alexander is past Chair and a current member of FDA’s Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.
    Patents/Royalties
    Dr. Alexander is past Chair and a current member of FDA’s Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.

Jerry Avorn

  • Nothing to Disclose

Shannon Brownlee

  • Nothing to Disclose

Cameron Camp

  • Nothing to Disclose

Howard Chertkow

  • Grants
    • Agency: 
      Hoffmann-La Roche Limited
      Dates: 
      2019-2022
    • Agency: 
      Lilly
      Dates: 
      2021-2022
    • Agency: 
      Abbvie Corporation
      Dates: 
      2018-2020
    • Agency: 
      Alector Co
      Dates: 
      2021-2022
    • Agency: 
      Anavex Life Sciences
      Dates: 
      2022
    • Agency: 
      Immunocal
      Dates: 
      2018-2022

Adriane Fugh-Berman

  • Patents/Royalties
    I am an expert witness on behalf of plaintiffs in litigation regarding pharmaceutical marketing practices. I have done no expert witness work on Alzheimer's drugs. My project at Georgetown University Medical Center receives some funding from Kaiser Permanente. I have a patent on a mint mask for asthma and bronchitis. There is no commercial sponsor and that is unrelated to this subject.

Sam Gandy

  • Nothing to Disclose

Daniel R. George

  • Nothing to Disclose

Robert Howard

  • Nothing to Disclose

Aaron Kesselheim

  • Nothing to Disclose

Kenneth M. Langa

  • Consulting Fees:
    I receive consulting fees for work on University-based NIH-funded research projects. I do not receive consulting fees from any for-profit company.
    Grants
    • Agency: 
      Alzheimer's Association
      Dates: 
      2018 to present

Eric B. Larson

  • Patents/Royalties
    Royalties from Up To Date for chapters I write

George Perry

  • Consulting Fees:
    Nervgen--Scientific Advisor Synaptogenix--Scientific Advisor (Chair)
    Equity:
    Synaptogenix Neurotez

Edo Richard

  • Nothing to Disclose

Vikas Saini

  • Equity:
    Health Data Analytics Institute (privately held) 1% The rest are all publicly traded in my retirement account: Mosaic Industries 1500 Nel Inc 236,000 ITM Power 23,500 Enapter 1100 Etsy 100

Lon Schneider

  • Consulting Fees:
    Eli Lilly, Neurim, Ltd, Cognition Therapeutics, Takeda, vTv, Roche/Genentech, Samus, Immunobrain Checkpoint, Biovie, Cortexyme, AC Immune, GW Research, Otsuka, Pharmatrophix, Alpha Cognition, Novo Nordisk, UCB, Vivli.org
    Grants
    • Agency: 
      Eisai
      Dates: 
      2021 -
    • Agency: 
      Eli Lilly
      Dates: 
      2015 -
    • Agency: 
      Biohaven
      Dates: 
      2018 - 2021
    • Agency: 
      Biogen
      Dates: 
      2015 -
    • Agency: 
      Novartis
      Dates: 
      2015 - 2021
    • Agency: 
      Washington University/ NIA, DIAN-TU R56AG053267
      Dates: 
      2016 -

Peter Whitehouse

  • Nothing to Disclose